glucagon has been researched along with ly2409021 in 6 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (ly2409021) | Trials (ly2409021) | Recent Studies (post-2010) (ly2409021) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 13 | 6 | 13 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deeg, MA; Fu, H; Garhyan, P; Kelly, RP; Lim, CN; Loh, MT; Pinaire, JA; Prince, MJ; Raddad, E | 1 |
| Agrawal, S; Gupta, Y | 1 |
| Deeg, MA; Ding, Y; Fu, H; Garhyan, P; Hardy, TA; Kazda, CM; Kelly, RP; Landschulz, WH; Lewin, AJ; Lim, CN; Moller, DE; Shi, C; Watson, DE | 1 |
| Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; van Hall, G; Vilsbøll, T | 1 |
| Forman, JL; Gasbjerg, LS; Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; Rosenkilde, MM; van Hall, G; Vilsbøll, T | 1 |
| Forman, JL; Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; Vilsbøll, T | 1 |
3 trial(s) available for glucagon and ly2409021
| Article | Year |
|---|---|
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.
Topics: Adult; Aged; Biphenyl Compounds; Cohort Studies; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Half-Life; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Molecular Targeted Therapy; Receptors, Glucagon; Risk; Single-Blind Method | 2015 |
The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes.
Topics: Adult; Aged; Biphenyl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Postprandial Period; Receptors, Glucagon | 2022 |
The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Topics: Biphenyl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucagon; Glucose; Humans; Incretins; Insulin; Receptors, Glucagon | 2022 |
3 other study(ies) available for glucagon and ly2409021
| Article | Year |
|---|---|
Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Topics: Biphenyl Compounds; Diabetes Mellitus, Type 2; Glucagon; Humans; Receptors, Glucagon | 2016 |
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Topics: Biphenyl Compounds; Diabetes Mellitus, Type 2; Glucagon; Humans; Receptors, Glucagon | 2016 |
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Topics: Benzhydryl Compounds; Biphenyl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Metabolism; Gastric Emptying; Glucagon; Glucosides; Glycerol; Half-Life; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2020 |